Search results for "dab"

showing 10 items of 1280 documents

Latvijas Universitātes Bibliotēkas jaunumi, 2016, Nr. 10

2016

Notikumu kalendārsBibliotēkas labākie darbinieki 2015.g.E-resursiIzstādes konferences un citi pasākumiZvaigžņotā debess - digitalizācijaĒnu dienaVizualizēta informācijaBibliotēkas statistika par 2015.gaduDabaszinātņu bibliotēkaBibliotēkas kolekcijasBibliotēka Raiņa bulvārī
researchProduct

Measurement of azimuthal asymmetries associated with deeply virtual Compton scattering on a longitudinally polarized deuterium target

2010

Azimuthal asymmetries in exclusive electroproduction of a real photon from a longitudinally polarized deuterium target are measured with respect to target polarization alone and with respect to target polarization combined with beam helicity and/or beam charge. The asymmetries appear in the distribution of the real photons in the azimuthal angle $\phi$ around the virtual photon direction, relative to the lepton scattering plane. The asymmetries arise from the deeply virtual Compton scattering process and its interference with the Bethe-Heitler process. The results for the beam-charge and beam-helicity asymmetries from a tensor polarized deuterium target with vanishing vector polarization ar…

Nuclear and High Energy Physics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyEVOLUTION KERNELS010308 nuclear & particles physicsGENERALIZED PARTON DISTRIBUTIONS; IMPACT PARAMETER SPACE; ELECTRON STORAGE-RING; EVOLUTION KERNELS; HERA; SPIN; NUCLEON; QCDHERAIMPACT PARAMETER SPACEFOS: Physical sciencesQCD01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ELECTRON STORAGE-RINGSPINGENERALIZED PARTON DISTRIBUTIONS0103 physical sciencesddc:530High Energy Physics::ExperimentSDG 7 - Affordable and Clean EnergyNUCLEON010306 general physics
researchProduct

Observation of charmonium pairs produced exclusively in $pp$ collisions

2014

A search is performed for the central exclusive production of pairs of charmonia produced in proton-proton collisions. Using data corresponding to an integrated luminosity of $3{\rm\ fb}^{-1}$ collected at centre-of-mass energies of 7 and 8 TeV, $J/\psi J/\psi$ and $J/\psi\psi(2S)$ pairs are observed, which have been produced in the absence of any other activity inside the LHCb acceptance that is sensitive to charged particles in the pseudorapidity ranges $(-3.5,-1.5)$ and $(1.5,5.0)$. Searches are also performed for pairs of P-wave charmonia and limits are set on their production. The cross-sections for these processes, where the dimeson system has a rapidity between 2.0 and 4.5, are measu…

Nuclear and High Energy PhysicsParticle physicsNuclear TheorydiffractionFOS: Physical sciencesLHCb - Abteilung HofmannHEAVY-ION COLLISIONSQCD diffraction charmoniaNOHigh Energy Physics - ExperimentLuminosityHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Quantum chromodynamiccharmonia; diffraction; QCDcharmonia; diffraction; QCD; Nuclear and High Energy PhysicsRapiditySDG 7 - Affordable and Clean EnergyNuclear ExperimentQCPhysics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyhep-ex12.38.-tParticle physicsHadron-induced high- and super-high-energy interactions (energy > 10 GeV): Inclusive production with identified hadronHEAVY-ION COLLISIONS; 450 GEV/C; DIFFRACTION; LHCQCDCromodinàmica quànticaLHCbDifracció450 GEV/CPseudorapidityPhysics::Accelerator PhysicscharmoniaFísica nuclearHigh Energy Physics::ExperimentProduction (computer science)LHCHEAVYFísica de partículesExperiments13.85.NiDiffractionQuantum chromodynamicsParticle Physics - ExperimentJournal of Physics G: Nuclear and Particle Physics
researchProduct

Measurement of the semileptonic branching fraction of the B_{s} meson

2012

We report a measurement of the inclusive semileptonic branching fraction of the B_s meson using data collected with the BaBar detector in the center-of-mass (CM) energy region above the Upsilon(4S) resonance. We use the inclusive yield of phi mesons and the phi yield in association with a high-momentum lepton to perform a simultaneous measurement of the semileptonic branching fraction and the production rate of B_s mesons relative to all B mesons as a function of CM energy. The inclusive semileptonic branching fraction of the B_s meson is determined to be B(B_s to l nu X)=9.5 (+2.5/-2.0)(stat)(+1.1/-1.9)(syst)%, where l indicates the average of e and mu.

Nuclear and High Energy PhysicsParticle physicssemileptonic branching fractionMesonHigh Energy Physics::Latticesemileptonic branching fraction B_s mesonFOS: Physical sciences01 natural sciencesResonance (particle physics)semileptonic Bs-meson decaysHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Mesons (Nuclear physics)B mesonSDG 7 - Affordable and Clean EnergyMesons (Física nuclear)010306 general physicsNuclear Experiment14.40.Nd 13.20.HePhysics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energy010308 nuclear & particles physicsBranching fractionLeptons (Física nuclear)High Energy Physics::PhenomenologyBABAR detectorbranching fraction measurementHEPPACS: 14.40.Nd 13.20.HeBaBar detector at SLAC; semileptonic Bs-meson decays; branching fraction measurementLeptons (Nuclear physics)Yield (chemistry)BaBarB_s mesonHigh Energy Physics::ExperimentBaBar detector at SLACsemileptonic Bs-meson decayLeptonProduction rate
researchProduct

Energy calibration of the NEXT-White detector with 1% resolution near Q ββ of 136Xe

2019

Excellent energy resolution is one of the primary advantages of electroluminescent high pressure xenon TPCs, and searches for rare physics events such as neutrinoless double-beta decay ($\beta\beta0\nu$) require precise energy measurements. Using the NEXT-White detector, developed by the NEXT (Neutrino Experiment with a Xenon TPC) collaboration, we show for the first time that an energy resolution of 1% FWHM can be achieved at 2.6 MeV, establishing the present technology as the one with the best energy resolution of all xenon detectors for $\beta\beta0\nu$ searches.

Nuclear and High Energy PhysicsPhysics - Instrumentation and DetectorsPhysical measurementsPhysics::Instrumentation and DetectorsDark Matter and Double Beta DecayFísica -- Mesuramentschemistry.chemical_elementBioengineeringAtomic01 natural sciencesMathematical SciencesNuclear physicsParticle and Plasma PhysicsXenonAffordable and Clean Energy0103 physical sciencesDark Matter and Double Beta Decay (experiments)CalibrationNuclearlcsh:Nuclear and particle physics. Atomic energy. RadioactivityCalibratge010306 general physicsMathematical PhysicsPhysicsQuantum Physics010308 nuclear & particles physicsDetectorResolution (electron density)MolecularDetectorsNuclear & Particles PhysicsFull width at half maximumchemistryBeta (plasma physics)Physical SciencesCalibrationlcsh:QC770-798High Energy Physics::ExperimentNeutrinoEnergy (signal processing)
researchProduct

Smarter Open Government Data for Society 5.0: Are Your Open Data Smart Enough?

2021

Nowadays, governments launch open government data (OGD) portals that provide data that can be accessed and used by everyone for their own needs. Although the potential economic value of open (government) data is assessed in millions and billions, not all open data are reused. Moreover, the open (government) data initiative as well as users’ intent for open (government) data are changing continuously and today, in line with IoT and smart city trends, real-time data and sensor-generated data have higher interest for users. These “smarter” open (government) data are also considered to be one of the crucial drivers for the sustainable economy, and might have an impact on information and communi…

OGD portalIndustry 4.0Internet privacyopen datareal-timeTP1-1185BiochemistryArticleAnalytical ChemistryInventionssensorSmart cityopen government data050602 political science & public administrationElectrical and Electronic EngineeringCitiesInstrumentationEcosystemOpen governmentGovernmentsmart portalmachine-redabilitybusiness.industryChemical technologyCommunication05 social sciencesOGDCOVID-19Industry 4.0sustainabilityAtomic and Molecular Physics and Optics0506 political scienceSociety 5.0Open dataCurrencyInformation and Communications TechnologyGovernmentSustainabilitysmart society smart datatimeliness0509 other social sciences050904 information & library sciencesbusinesscurrentnessSensors (Basel, Switzerland)
researchProduct

Biopolymeric porous structure for selective oil sorption and activity intensification of oil-degrading bacteria

2017

Oil pollution is one of the environmental concerns that are currently becoming a major issue in the petroleum industry. Among the different methods for environmental cleaning, the use of sorbents to recover the spilled oils is becoming more and more attractive because of their peculiar advantages such as reusability and recoverability of the oil. In this context, bioremediation is often considered a promising and cost-effective technology that could help a more sustainable recovery of contaminated water by using oil-degrading microorganisms. In this work, it is proposed a PCL-based biodegradable and floatable oil removal sponge, able to immobilize and increase biodegradation ability of hydr…

Oil/water separationBiodegradable polymeric spongeMelt polymer processing
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of r…

2015

BackgroundAcquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.MethodsWe compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.ResultsAmong 132 samples, putative resistance mechanisms were identified in 58%, including NRAS o…

OncologyNeuroblastoma RAS viral oncogene homologMaleCancer ResearchSkin NeoplasmsTime FactorsResistanceDNA Mutational AnalysisDrug ResistanceMedizinKaplan-Meier EstimateBioinformaticsmedicine.disease_causeRisk Factors2.1 Biological and endogenous factorsAetiologyVemurafenibMelanomaCancerMutationTumorDabrafenibMelanomaAcquiredMiddle AgedPhenotypeEuropePhenotypeTreatment OutcomeSpliceOncologyMeta-analysisPublic Health and Health ServicesDisease ProgressionFemalemedicine.drugSignal TransductionProto-Oncogene Proteins B-rafmedicine.medical_specialtyOncology and CarcinogenesisNRASAntineoplastic AgentsBiologyDisease-Free SurvivalArticleBRAFMEK1Clinical ResearchInternal medicineGeneticsmedicineBiomarkers TumorHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisProtein Kinase InhibitorsProportional Hazards ModelsProportional hazards modelAustraliaDabrafenibmedicine.diseaseMAPKUnited StatesMeta-analysisVemurafenibDrug Resistance NeoplasmMutationNeoplasmBiomarkersEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities.

2015

The introduction of small molecule BRAFV600 kinase inhibitors represents a milestone in the targeted therapy of patients with metastatic melanoma by a significant increase in therapeutic efficacy in terms of overall and progression-free survival compared with conventional chemotherapy. Beside BRAFV600 inhibitor treatment, radiotherapy is a further mainstay for the therapy of metastatic melanoma and thus a concomitant or sequential application of BRAFV600 inhibitors and radiotherapy is inevitable. Recent reports show a significant radiosensitization of the irradiated healthy tissue in patients with melanoma after the combination of radiotherapy and BRAFV600 inhibitors, evoking concern in cl…

OncologyProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyBRAF inhibitormedicine.medical_treatmentRadiation ToleranceTargeted therapy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicineCombined Modality TherapyHumansVemurafenibneoplasmsMelanomaProtein Kinase Inhibitorsbusiness.industryMelanomaDabrafenibGeneral Medicinemedicine.diseaseCombined Modality TherapyRadiation therapyOncology030220 oncology & carcinogenesisConcomitantMutationbusinessmedicine.drugFuture oncology (London, England)
researchProduct